SEARCH
Search Details
BOU RyousukeUniversity Hospital / Department of Mental Health for Children and ParentsAssociate Professor
Research activity information
■ Paper- The coronavirus disease 2019 (COVID-19) pandemic has affected people worldwide, and pediatric patients with underlying diseases are at high risk of developing severe COVID-19. However, there are limited reports on the clinical impact of COVID-19, especially in patients with underlying neuromuscular diseases (NMD) and inborn errors of metabolism (IEM). This study aimed to investigate the incidence and clinical presentation of COVID-19 in patients with NMD and IEM. This was a single-center, cross-sectional study of patients with NMD and IEM in Japan for 2 years, from April 1, 2020 to March 31, 2022. Among 255 participants with a median age of 14 (range: 0-50) years, 192 (75%) and 63 (25%) had NMD and IEM, respectively. Among 255 patients, 8 (5 NMD and 3 IEM) were positive for the anti-severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody, and the incidence was considered 3%. All positive patients had mild or asymptomatic COVID-19. None of the patients exhibited moderate or severe symptoms. In conclusion, this study revealed that the incidence of COVID-19 was low, and mild or subclinical infection was common even in patients with NMD and IEM, who may be at a higher risk of severe COVID-19.Feb. 2025, The Kobe journal of medical sciences, 70(4) (4), E106-E112, English, Domestic magazineScientific journal
- (一社)日本マススクリーニング学会, Jul. 2024, 日本マス・スクリーニング学会誌, 34(2) (2), 209 - 209, Japanese
- (一社)日本小児神経学会, Mar. 2024, 脳と発達, 56(2) (2), 151 - 151, Japanese
- (一社)日本小児神経学会, Mar. 2024, 脳と発達, 56(2) (2), 152 - 152, Japanese
- Newborn screening (NBS) for spinal muscular atrophy (SMA) is necessary, as favorable outcomes can be achieved by treatment with disease-modifying drugs in early infancy. Although SMA-NBS has been initiated in Japan, its clinical results have not been fully reported. We report the findings of the initial 2.5 years of a pilot SMA-NBS of approximately 16,000 infants conducted from February 2021 in Hyogo Prefecture, Japan. Clinical data of 17 infants who tested positive were retrospectively obtained from the NBS follow-up centers participating in this multicenter cohort observational study. Genetic testing revealed 14 false positives, and three infants were diagnosed with SMA. Case 1 had two copies of survival motor neuron (SMN) 2 and showed SMA-related symptoms at diagnosis. Case 2 was asymptomatic, with two copies of SMN2. Asymptomatic case 3 had four copies of SMN2 exon 7, including the SMN1/2 hybrid gene. Cases 1 and 2 were treated within 1 month and case 3 at 8 months. All the patients showed improved motor function scores and did not require respiratory support. The identification of infants with SMA via NBS and early treatment improved their motor and respiratory outcomes. Thus, implementation of SMA-NBS at a nationwide scale should be considered.MDPI AG, Dec. 2023, Genes, 14(12) (12), 2211 - 2211Scientific journal
- Elsevier BV, Nov. 2023, Journal of Cardiology, 82(5) (5), 363 - 370Scientific journal
- (一社)日本マススクリーニング学会, Aug. 2023, 日本マス・スクリーニング学会誌, 33(2) (2), 260 - 260, Japanese
- (一社)日本マススクリーニング学会, Aug. 2023, 日本マス・スクリーニング学会誌, 33(2) (2), 260 - 260, Japanese
- (一社)日本遺伝カウンセリング学会, Jun. 2023, 日本遺伝カウンセリング学会誌, 44(2) (2), 163 - 163, Japanese
- (一社)日本小児神経学会, May 2023, 脳と発達, 55(Suppl.) (Suppl.), S319 - S319, Japanese
- (一社)日本小児神経学会, May 2023, 脳と発達, 55(Suppl.) (Suppl.), S323 - S323, Japanese
- (公社)日本小児科学会, Apr. 2023, 日本小児科学会雑誌, 127(4) (4), 627 - 627, JapaneseCOVID-19感染症を契機に急性増悪した全身型重症筋無力症の女児例
- The authors wish to make the following correction to this paper [...].Mar. 2023, Genes, 14(3) (3), English, International magazine
- (一社)日本内分泌学会, Feb. 2023, 日本内分泌学会雑誌, 98(4) (4), 1035 - 1035, Japanese
- Multiple acyl-CoA dehydrogenase deficiency (MADD) is an inherited metabolic disease caused by a defect in electron transfer flavoprotein alpha (ETFA), ETF beta (ETFB), or ETF dehydrogenase (ETFDH), and riboflavin metabolism disorders have recently been reported to present as mimicking MADD. MADD is roughly classified into neonatal (type 1 or 2) and later-onset (type 3) forms. To identify clinicogenetic characteristics in Japan, we investigated 37 Japanese patients with MADD diagnosed from 1997 to 2020. The causes of MADD were ETFDH deficiency in 26 patients, ETFA deficiency in four, ETFB deficiency in six, and riboflavin metabolism disorder in one. All 15 patients with the neonatal-onset type died by 2 years of age, while five of 22 patients with the later-onset form died by 3 years of age. Furthermore, 8 of 15 patients with the later-onset form of ETFDH deficiency treated with riboflavin were riboflavin non-responders. p.Y507D in ETFDH was identified as the most common variant (9 of 48 alleles, 18.8%). Of two patients with a homozygous p.Y507D variant, one experienced disease onset and died in the neonatal period, while the other experienced disease onset at two months of age and died at two years old, suggesting that the p.Y507D variant results in fatal outcomes. Our study concluded that more than half of Japanese patients with MADD died by three years old, and more than half of patients with the later-onset form had poor responsiveness to riboflavin, partly due to the unique Japanese p.Y507D variant in ETFDH.Dec. 2022, Molecular genetics and metabolism reports, 33, 100940 - 100940, English, International magazineScientific journal
- Spinal muscular atrophy (SMA) is a common devastating neuromuscular disorder, usually involving homozygous deletion of the SMN1 gene. Newly developed drugs can improve the motor functions of infants with SMA when treated in the early stage. To ensure early diagnosis, newborn screening for SMA (SMA-NBS) via PCR-based genetic testing with dried blood spots (DBSs) has been spreading throughout Japan. In Hyogo Prefecture, we performed a pilot study of SMA-NBS to assess newborn infants who underwent routine newborn metabolic screening between February 2021 and August 2022. Hyogo Prefecture has ~40,000 live births per year and the estimated incidence of SMA is 1 in 20,000-25,000 based on genetic testing of symptomatic patients with SMA. Here, we screened 8336 newborns and 12 screen-positive cases were detected by real-time PCR assay. Multiplex ligation-dependent probe amplification assay excluded ten false positives and identified two patients. These false positives might be related to the use of heparinized and/or diluted blood in the DBS sample. Both patients carried two copies of SMN2, one was asymptomatic and the other was symptomatic at the time of diagnosis. SMA-NBS enables us to prevent delayed diagnosis of SMA, even if it does not always allow treatment in the pre-symptomatic stage.Nov. 2022, Genes, 13(11) (11), English, International magazineScientific journal
- (一社)日本先天代謝異常学会, Oct. 2022, 日本先天代謝異常学会雑誌, 38, 187 - 187, Japaneseシトルリン低値による遅発型OTC欠損症・CPS1欠損症に対する新生児スクリーニング
- (一社)日本先天代謝異常学会, Oct. 2022, 日本先天代謝異常学会雑誌, 38, 193 - 193, Japanese死亡時のアシルカルニチン分析結果を契機に確定診断したグルタル酸血症2型の一例
- (一社)日本先天代謝異常学会, Oct. 2022, 日本先天代謝異常学会雑誌, 38, 215 - 215, Japanese糖原病9a型の3家系6人における食事療法開始後の身長の推移
- (一社)日本マススクリーニング学会, Aug. 2022, 日本マス・スクリーニング学会誌, 32(2) (2), 233 - 233, Japanese
- (一社)日本小児神経学会, Jul. 2022, 脳と発達, 54(4) (4), 262 - 265, Japanese
- (一社)日本小児神経学会, May 2022, 脳と発達, 54(Suppl.) (Suppl.), S210 - S210, Japanese
- (公社)日本小児科学会, Mar. 2022, 日本小児科学会雑誌, 126(3) (3), 545 - 545, Japanese初回発症時にMASを合併した若年性特発性若年性関節炎の1例
- (公社)日本小児科学会, Mar. 2022, 日本小児科学会雑誌, 126(3) (3), 547 - 547, Japanese兵庫県における治療可能となった難病に対する拡大新生児マススクリーニングの取り組み
- (公社)日本小児科学会, Mar. 2022, 日本小児科学会雑誌, 126(3) (3), 551 - 551, Japanese過去5年間の小児摂食障害に対する家族療法の経験
- Jan. 2022, Pediatrics international : official journal of the Japan Pediatric Society, 64(1) (1), e15021, English, International magazineScientific journal
- (一社)日本先天代謝異常学会, Sep. 2021, 日本先天代謝異常学会雑誌, 37, 131 - 131, Japanese極低出生体重児におけるビオチンおよびビオチン関連代謝産物の推移
- (一社)日本先天代謝異常学会, Sep. 2021, 日本先天代謝異常学会雑誌, 37, 158 - 158, Japanese著しい高アンモニア血症がない急性肝障害から診断したOTC欠損症の一例
- (一社)日本先天代謝異常学会, Sep. 2021, 日本先天代謝異常学会雑誌, 37, 163 - 163, Japanese尿中有機酸分析がHMG-CoA合成酵素欠損症の発症早期診断に有用であった乳児の一例
- (一社)日本先天代謝異常学会, Sep. 2021, 日本先天代謝異常学会雑誌, 37, 131 - 131, Japanese極低出生体重児におけるビオチンおよびビオチン関連代謝産物の推移
- Very long-chain acyl-coenzyme A dehydrogenase deficiency (VLCADD, OMIM 201475) is a congenital fatty acid oxidation disorder. Individuals with VLCADD should avoid catabolic states, including strenuous exercise and long-term fasting; however, such conditions are required when undergoing surgery. The perioperative management of VLCADD in infants has rarely been reported and details regarding the transition of serum biomarkers reflecting catabolic status have not been disclosed. Herein, we present the perioperative clinical and biological data of cryptorchidism in a 1.5-year-old boy with VLCADD. The patient was diagnosed through newborn screening and his clinical course was very stable. Genetic testing of ACADVL revealed compound heterozygous variants c.506 T > C (p.Met169Thr) and c.606-609delC (p.L216*). The enzyme activity of the patient with VLCAD was only 20% compared to that of healthy control. Left orchiopexy for the pediatric cryptorchidism was planned and performed at 1 and a half year of age. Induction anesthesia involved thiopental, fentanyl and rocuronium. The glucose infusion rate was maintained above 6.6 mg/kg/min starting the day before surgery until the operation was completed. Anesthesia was maintained with sevoflurane at approximately 2%. The serum concentration of tetradecenoylcarnitine were stable during the operation, ranging between 0.08 and 0.19 μM (cutoff <0.2 μM), and never deviated from the reference range. Concentration of other serum biomarkers including free fatty acid, 3-OH-butyrate, and creatine kinase, remained similarly unchanged. In this report, we describe the uneventful perioperative management of unilateral orchiopexy for left cryptorchidism in a 1.5-year-old boy with VLCADD using sufficient glucose infusion and volatile anesthesia.Jun. 2021, Molecular genetics and metabolism reports, 27, 100760 - 100760, English, International magazine
- (一社)日本マススクリーニング学会, May 2021, 日本マス・スクリーニング学会誌, 31(1) (1), 41 - 47, Japanese
- (公社)日本小児科学会, Apr. 2021, 日本小児科学会雑誌, 125(4) (4), 673 - 673, Japanese新生児スクリーニングにおけるシトルリン低値を用いたオルニチントランスカルバミラーゼ(OTC)欠損症スクリーニングの可能性
- BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal progressive muscle-wasting disease caused by mutations in the DMD gene. Dilated cardiomyopathy is the leading cause of death in DMD; therefore, further understanding of this complication is essential to reduce morbidity and mortality. METHODS: A common null variant (R577X) in the ACTN3 gene, which encodes α-actinin-3, has been studied in association with muscle function in healthy individuals; however it has not yet been examined in relationship to the cardiac phenotype in DMD. In this study, we determined the ACTN3 genotype in 163 patients with DMD and examined the correlation between ACTN3 genotypes and echocardiographic findings in 77 of the 163 patients. RESULTS: The genotypes 577RR(RR), 577RX(RX) and 577XX(XX) were identified in 13 (17%), 44 (57%) and 20 (26%) of 77 patients, respectively. We estimated cardiac involvement-free survival rate analyses using Kaplan-Meier curves. Remarkably, the left ventricular dilation (> 55 mm)-free survival rate was significantly lower in patients with the XX null genotype (P < 0.01). The XX null genotype showed a higher risk for LV dilation (hazard ratio 9.04). CONCLUSIONS: This study revealed that the ACTN3 XX null genotype was associated with a lower left ventricular dilation-free survival rate in patients with DMD. These results suggest that the ACTN3 genotype should be determined at the time of diagnosis of DMD to improve patients' cardiac outcomes.Oct. 2020, Journal of cardiac failure, 26(10) (10), 841 - 848, English, International magazineScientific journal
- (一社)日本マススクリーニング学会, Sep. 2020, 日本マス・スクリーニング学会誌, 30(2) (2), 135 - 135, Japanese
- Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, a condition in which the body is unable to break down long-chain fatty acids properly, is the most common fatty acid oxidation disorder in Japan. Tandem mass spectrometry has been used in newborn screening (NBS), allowing the detection of patients with VLCAD deficiency even before symptoms manifest. However, tandem mass spectrometry has a high false positive rate. We investigated the clinical characteristics of patients with false positive results for tetradecenoyl acylcarnitine (C14:1). This case-control study used data collected between the 1st of January 2014 and the 31st of March 2019. The case group was defined as patients having levels of both C14:1 and C14:1/C2 ratio higher than cut-off levels in the first newborn mass screening, who were eventually diagnosed as false positives by attending doctors at Kobe University Hospital, Palmore Hospital, or Kakogawa Central City Hospital in Japan. The control group comprised 100 patients randomly selected from the three facilities. The false positive group included 17 cases, and the control group contained 300 patients. The demographics of each group did not show any significant differences in sex, body weight at birth, Cesarean section rate, complete breastfeeding rate, or the number of feedings per day. However, the change in body weight at the sampling day of NBS in the false positive and control groups was -10.2%, and - 4.6%, respectively, showing a statistically significant difference (p < 0.01). In addition, body weight gain at the one-month medical checkup was 38.9 g/day in the false positive group and 44.1 g/day in the control group (p < 0.05). An elevation of C14:1 carnitine has been reported in situations involving the catalysis of fatty acid. Therefore, patients with severe body weight loss might be associated with poor sucking or poor milk supply, which might cause a false positive elevation of C14:1 and C14:1/C2. In suspected VLCAD deficiency, attending doctors should pay attention to body weight changes recorded during newborn mass screening.Sep. 2020, Molecular genetics and metabolism reports, 24, 100634 - 100634, English, International magazineScientific journal
- In Japan, carnitine palmitoyltransferase II (CPTII) deficiency has been included as one of the primary target diseases in the expanded newborn mass screening program since 2018. However, many cases of the severe infantile hepatocardiomuscular form of CPTII deficiency showed severe neurodevelopmental delay or sudden death, which indicated that management of CPTII deficiency in the acute phase remains to be studied in detail. Herein, we discuss two cases diagnosed by newborn mass screening. Patient 1 was under strict clinical management from the neonatal period, with >20 admissions in 14 months, while Patient 2 was managed using a relatively relaxed approach, with only 2 admissions in the same period. Patient 1 showed normal development; however, Patient 2 expired at the age of 1 year 2 months. To develop strategies for preventing sudden deaths in patients with CPTII deficiency, this retrospective study focused on detailed clinical management practices and biochemical findings during the acute phase. We also investigated the correlation between conventional biomarkers (such as creatine kinase) and long-chain acylcarnitines. We propose that strict monitoring and immediate medical attention, even in case of slight fever or minor abdominal symptoms, can help prevent sudden death in patients with CPTII deficiency. Considering the higher morbidity rate of such patients, strict and acute management of CPTII deficiency cannot be overemphasized.Sep. 2020, Molecular genetics and metabolism reports, 24, 100611 - 100611, English, International magazine[Refereed]
- (一社)日本小児神経学会, Aug. 2020, 脳と発達, 52(Suppl.) (Suppl.), S248 - S248, Japanese
- (一社)日本小児神経学会, Aug. 2020, 脳と発達, 52(Suppl.) (Suppl.), S300 - S300, Japanese
- (株)メディカルレビュー社, Apr. 2020, The Lipid, 31(1) (1), 91 - 91, JapaneseCPT2欠損症では厳格な入院管理体制が必要である
- (株)日本小児医事出版社, Apr. 2020, 小児科臨床, 73(4) (4), 499 - 502, Japanese
- (公社)日本小児科学会, Feb. 2020, 日本小児科学会雑誌, 124(2) (2), 405 - 405, Japanese胃腸炎回復期に低血糖を起こした中鎖アシルCoA脱水素酵素(MCAD)欠損症の一例
- (公社)日本小児科学会, Dec. 2019, 日本小児科学会雑誌, 123(12) (12), 1812 - 1818, Japanese
- 日本先進糖尿病治療研究会, Nov. 2019, 日本先進糖尿病治療研究会雑誌, 15, 46 - 46, Japanese兵庫県内の1型糖尿病患者に対するグルカゴン製剤の処方率
- 日本マススクリーニング学会, Oct. 2019, 日本マス・スクリーニング学会誌, 29(2) (2), 190 - 190, Japanese新生児マススクリーニングにおけるC14:1偽陽性例では出生後の体重減少が大きい[Refereed]
- BACKGROUND: Mechanical insufflation-exsufflation (MI-E) is necessary for noninvasive management of respiratory clearance in patients with neuromuscular disorders (NMDs). Its utility has been proven, and the technique is recommended in a number of international guidelines for the management of patients with NMDs. However, the clearance of thick secretions adhering to the tracheobronchial walls could be problematic when these patients suffer from respiratory tract infections. To improve the effectiveness of the noninvasive technique, a novel device combining MI-E with high frequency oscillation (HFO) has been developed. However, the efficacy of HFO therapy in NMDs has not been well studied. OBJECTIVE: The aim of this study was to elucidate the effect of MI-E combined with HFO for mucus removal in NMD patients. To evaluate its efficacy, changes in transcutaneous oxygen saturation (SpO2), which may predict intratracheal mucus removal, will be measured before and after use of MI-E. METHODS: This is a single-center, nonblinded, nonrandomized prospective study that will enroll 5 subjects hospitalized in Kobe University Hospital owing to respiratory tract infection. All subjects will receive MI-E therapy a few times daily and will receive HFO every other day, for 6 days. Before and after MI-E use, SpO2 will be obtained and the change in SpO2 (ΔSpO2) between MI-E with and without HFO will be calculated. For every subject, the average of ΔSpO2 with or without HFO will be obtained and the null hypothesis that there is a mean change of 0 in the SpO2 between MI-E with and without HFO will be tested using the paired t test. If the treatment with HFO is found to be statistically significantly superior to the treatment without HFO, the study will conclude that HFO addition is more efficacious than no HFO addition. RESULTS: A total of 2 subjects have already been recruited and enrolled in this study as of August 2018. CONCLUSIONS: This unique protocol will assess the efficacy of adding HFO to MI-E during the acute phase of respiratory tract infection in patients with NMDs. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/12102.Jun. 2019, JMIR research protocols, 8(6) (6), e12102, English, International magazine[Refereed]Scientific journal
- (一社)日本小児神経学会, May 2019, 脳と発達, 51(Suppl.) (Suppl.), S264 - S264, JapaneseDuchenne型筋ジストロフィー患者を対象としたわさびの根茎に含まれるスルフィニル成分の筋崩壊抑制効果の検討
- PURPOSE: Hypoglycemia is a common and life-threatening complication in type 1 diabetes mellitus (T1DM) patients. Current guidelines recommend glucagon for treating hypoglycemia in out-of-hospital settings; however, glucagon is reportedly underused in such patients. We conducted a doctor-oriented, questionnaire-based survey of pediatricians and physicians to determine the glucagon prescription rate and identify the reason(s) for its underuse in T1DM patients. METHODS: A questionnaire was mailed to 415 pediatricians and 200 physicians employed at 66 facilities with >100 general wards throughout Hyogo, Japan. The following variables were surveyed: doctor's specialty, glucagon prescription rate, familiarity with glucagon use guidelines, barriers to prescribing glucagon, and attitude changes after education. RESULTS: After 16 doctors were found to have retired, 599 doctors were enrolled; 305 (187 pediatricians and 118 physicians) returned a completed questionnaire. In all, 45 pediatricians and 104 physicians were treating T1DM patients, of whom 24% and 28% reported prescribing glucagon, respectively. The guideline familiarity rate among pediatricians was lower than that among physicians. The major barrier to prescribing glucagon was the complex preparation procedure required by patients/caregivers. More than half of the doctors who did not prescribe glucagon began doing so after being educated about the guidelines. CONCLUSION: The glucagon prescription rate was low among both pediatricians and physicians in Japan.May 2019, Endocrine, 64(2) (2), 233 - 238, English, International magazine[Refereed]
- (一社)日本糖尿病学会, Apr. 2019, 糖尿病, 62(4) (4), 257 - 257, Japanese兵庫県内の糖尿病内科医の1型糖尿病患者に対するグルカゴン製剤の処方実態
- 日本先進糖尿病治療研究会, Nov. 2018, 日本先進糖尿病治療研究会雑誌, 14, 39 - 39, JapaneseFreeStyle Libreの1型糖尿病患者での測定精度に関する検討
- (一社)大分市医師会, Jun. 2018, アルメイダ医報, 43(1) (1), 55 - 59, Japaneseタンデムマス法による新生児マススクリーニング検査により早期診断した原発性全身性カルニチン欠乏症の乳児例
- Jan. 2018, Pediatrics International (Web), 60(1) (1), 67‐69, EnglishRenal insufficiency mimicking glutaric acidemia type 1 on newborn screening[Refereed]Scientific journal
- BACKGROUND: Glutaryl carnitine (C5DC) in dried blood spots is used as a biomarker for glutaric aciduria type 1 (GA-1) screening. C5DC, however, is the only screening marker for this condition, and various pathological conditions may interfere with C5DC metabolism. Recently, C5DC elevation has been reported in cases of renal insufficiency. METHOD: Five patients who were positive for GA-1 on newborn screening with tandem mass spectrometry between September 2012 and March 2015 at Kobe University Hospital were enrolled in this study. RESULTS: GA-1 was not confirmed on urinary organic acids analysis in any of the patients. C5DC decreased immediately in four patients, but one patient, who had high C5DC for at least 4 months, was diagnosed with bilateral renal hypoplasia. CONCLUSION: In the case of persistently elevated C5DC, renal insufficiency should be considered as a differential diagnosis.Jan. 2018, Pediatrics international : official journal of the Japan Pediatric Society, 60(1) (1), 67 - 69, English, International magazine[Refereed]Scientific journal
- Nov. 2017, MOLECULAR GENETICS AND METABOLISM, 122(3) (3), 67 - 75, English[Refereed]Scientific journal
- Sep. 2017, JOURNAL OF HUMAN GENETICS, 62(9) (9), 809 - 814, English[Refereed]Scientific journal
- Elsevier Inc., Jun. 2017, Molecular Genetics and Metabolism Reports, 11, 59 - 61, English[Refereed]Scientific journal
- (一社)日本小児神経学会, May 2017, 脳と発達, 49(Suppl.) (Suppl.), S360 - S360, Japanese
- (一社)日本糖尿病学会, Apr. 2017, 糖尿病, 60(Suppl.1) (Suppl.1), S - 379, Japanese幼児期からの糖・脂質代謝の経過をフォローしえたPTRF遺伝子変異による全身性脂肪萎縮症の一例
- Apr. 2017, Brain & Development, 39(3 Supplement) (3 Supplement), 330, EnglishEfficacy and Complications of Fosphenytoin Versus Continuous Midazolam in Children with Febrile Status Epilepticus[Refereed]Scientific journal
- (公社)日本小児科学会, Feb. 2017, 日本小児科学会雑誌, 121(2) (2), 374 - 374, Japanese超低出生体重児のSGA性低身長症に対する成長ホルモン治療の検討
- Jan. 2017, BRAIN & DEVELOPMENT, 39(1) (1), 48 - 57, English[Refereed]Scientific journal
- Germline intragenic mutations in the GNAS locus result in pseudohypoparathyroidism type 1a (PHP1a) and related conditions. Nearly half of the previously reported GNAS intragenic mutations were structural variants, including 3 tandem duplications of 12-25 bp. However, the precise mutation spectrum and the genomic basis of GNAS structural variants remain to be clarified. Here, we report a de novo 50-bp tandem duplication in GNAS (c.723_772dup50, p.Glu259Leufs*29) identified in a patient with typical clinical features of PHP1a. The mutant transcript was predicted to undergo mRNA decay or encode a nonfunctional protein. The 2 breakpoints of the duplication shared a 1-bp microhomology but were not associated with long homology or nucleotide stretches. We also examined the breakpoint structures of 3 previously reported GNAS duplications and found that 1 had a structure similar to that of our case, while the remaining 2 had blunt-ended breakpoints without microhomologies. In silico analyses revealed that the GNAS-flanking region was not enriched with repeats, palindromes, noncanonical DNA motifs, or GC content. This study expands the mutation spectrum of GNAS and provides the first indication that GNAS intragenic structural variants are induced by multiple processes, including nonhomologous end-joining and/or microhomology-mediated break-induced replication, independently of known rearrangement-inducing DNA features.2017, Cytogenetic and genome research, 153(3) (3), 125 - 130, English, International magazine[Refereed]Scientific journal
- Nov. 2016, 特殊ミルク情報, (52) (52), 48 - 51, Japanese頻回の入院管理によって代謝不全を予防したカルニチンパルミトイルトランスフェラーゼ(CPT)-2欠損症の1例Scientific journal
- (一社)日本医用マススペクトル学会, Aug. 2016, JSBMS Letters, 41(Suppl.) (Suppl.), 50 - 50, JapaneseLC-MS/MSによる血清中アシルカルニチンの定量分析の新規非誘導体化法の開発及び既存簡易測定法との比較検討
- Mar. 2016, BRAIN & DEVELOPMENT, 38(3) (3), 293 - 301, English[Refereed]Scientific journal
- (公社)日本小児科学会, Jan. 2016, 日本小児科学会雑誌, 120(1) (1), 91 - 91, Japaneseインフルエンザ罹患を機に意識障害を呈し、ミトコンドリアHMG-CoA合成酵素欠損症と診断した1例
- Metabolic Survey of Hidden Inherited Metabolic Diseases in Children With Apparent Life-Threatening Event(ALTE)or Sudden Unexpected Death in Infancy(SUDI)by Analyses of Organic Acids and Acylcarnitines Using Mass SpectrometriesTo determine the relation between sudden unexpected death in infancy (SUDI) or apparent lifethreatening events (ALTE) and inborn errors of metabolism (IMD), we investigated clinical and biochemical features in patients presenting with SUDI or ALTE, who were diagnosed with having hidden IMD. Subjects were infants between aged from 2 days and 3 years, detected during the period bShimane University Faculty of Medicine, 2016, Shimane journal of medical science, 32(2) (2), 61 - 68, English[Refereed]Scientific journal
- Nov. 2015, Molecular genetics and metabolism, 116(3) (3), 192 - 4, English, International magazine[Refereed]Scientific journal
- A fetus with mitochondrial trifunctional protein deficiency: Elevation of 3-OH-acylcarnitines in amniotic fluid functionally assured the genetic diagnosis.Mitochondrial trifunctional protein (TFP) is a multienzyme complex that catalyzes the last three steps of the β-oxidation cycle of long-chain fatty acids. In the prenatal diagnosis of TFP deficiency, acylcarnitine (AC) analysis has been considered difficult because of limited excretion of long-chain ACs into the fetal urine and hence into the amniotic fluid. Here, we report ourNov. 2015, Mol Genet Metab Rep., 5(6) (6), 1 - 4, English[Refereed]Scientific journal
- (一社)日本医用マススペクトル学会, Aug. 2015, JSBMS Letters, 40(Suppl.) (Suppl.), 78 - 78, Japanese臨床検査を目的としたLC-MS/MSによる血清中アシルカルニチンの定量分析法の開発
- 2021, 日本小児科学会雑誌, 125(2) (2)A SMA1 infant who received Zolgensma therapy at the age of 50 days
- 2020, 日本小児科学会雑誌, 124(6) (6)胃腸炎罹患後に低血糖発作をおこした中鎖アシルCoA脱水素酵素(MCAD)欠損症の1例
- 2020, 日本小児科学会雑誌, 124(6) (6)治療抵抗性の眼筋型重症筋無力症に対してステロイドパルス療法を行った2歳女児例
- (一社)日本小児神経学会, May 2019, 脳と発達, 51(Suppl.) (Suppl.), S288 - S288, Japanese1歳以降にヌシネルセン治療を開始した脊髄性筋萎縮症1型の3例
- (一社)日本小児神経学会, May 2019, 脳と発達, 51(Suppl.) (Suppl.), S288 - S288, Japanese1歳以降にヌシネルセン治療を開始した脊髄性筋萎縮症1型の3例
- (公社)日本小児科学会, Mar. 2019, 日本小児科学会雑誌, 123(3) (3), 615 - 615, Japanese酵素活性・負荷試験で異常を認めなかった糖原病IXa型の2歳男児例
- (公社)日本小児科学会, Mar. 2019, 日本小児科学会雑誌, 123(3) (3), 623 - 623, Japanese新生児マススクリーニングを契機に発見された先天性乳糖不耐症の新生児例
- (公社)日本小児科学会, Mar. 2019, 日本小児科学会雑誌, 123(3) (3), 616 - 616, Japanese1型糖尿病患者に対するグルカゴンの処方実態
- 2019, 日本小児科学会雑誌, 123(3) (3)バセドウ病を合併した若年ミオクロニーてんかんの1例
- 2019, 日本小児科学会雑誌, 123(2) (2)幼児期からヌシネルセン治療を開始した脊髄性筋萎縮症3型の2例の経過
- 2019, 日本小児科学会雑誌, 123(3) (3)急性散在性脳脊髄炎の髄液所見の検討
- 日本先天代謝異常学会, Sep. 2018, 日本先天代謝異常学会雑誌, 34, 201 - 201, Japanese7歳時に診断した若年/成人型ガラクトシアリドーシスの臨床経過
- (一社)日本小児神経学会, May 2018, 脳と発達, 50(Suppl.) (Suppl.), S352 - S352, Japanese神戸大学における小児科と麻酔科の連携による脊髄性筋萎縮症のヌシネルセン治療
- 01 Apr. 2018, 日本小児科学会雑誌, 122(4) (4), 809, Japaneseカーボカウントが1型糖尿病の血糖管理に有用であった7歳男児例
- 01 Apr. 2018, 日本小児科学会雑誌, 122(4) (4), 816, Japanese先天性甲状腺機能低下症(CH)のフォロー中に偽性副甲状腺機能低下症と診断された1例
- 01 Apr. 2018, 日本小児科学会雑誌, 122(4) (4), 820, Japanese不明熱の精査中にRadiologically Isolated Syndromeが疑われた1例
- 01 Feb. 2018, 日本小児科学会雑誌, 122(2) (2), 460, Japanese2歳時に早期診断が出来た脊髄性筋萎縮症3a型の女児例
- 2018, 日本小児科学会雑誌, 122(4) (4)乳幼児感覚プロファイルを用いた発達障害児の感覚特性に関する検討
- 2018, 日本小児内分泌学会学術集会プログラム・抄録集, 52nd偶発的に発見された成長ホルモン産生下垂体腺腫の11歳男児例
- 2018, 日本小児内分泌学会学術集会プログラム・抄録集, 52nd, 228, Japanese発作性運動誘発性ジスキネジアを呈した偽性副甲状腺機能低下症の一例
- 12 Sep. 2017, 日本先天代謝異常学会雑誌, 33, 202, Japaneseカルニチンのみで良好な経過をたどる慢性進行型メチルマロン酸血症同胞例
- 01 May 2017, 日本小児科学会雑誌, 121(5) (5), 908‐909, JapaneseビタミンB12反応性メチルマロン酸血症の1例
- 01 Feb. 2017, 日本小児科学会雑誌, 121(2) (2), 374, Japanese超低出生体重児のSGA性低身長症に対する成長ホルモン治療の検討
- 01 Feb. 2017, 日本小児科学会雑誌, 121(2) (2), 380, Japanese近位筋優位の筋力低下から筋疾患が疑われたシャルコー・マリー・トゥース病2型
- 2017, 日本内分泌学会雑誌, 93(2) (2)CGMが診断・治療に有用であったダンピング症候群の乳児例
- 2017, 日本小児内分泌学会学術集会プログラム・抄録集, 51st, 207, Japanese新生児期に高TSH血症を示した偽性副甲状腺機能低下症の乳児期BMI
- 2017, 糖尿病(Web), 60(Suppl) (Suppl), S.379(J‐STAGE), Japanese幼児期からの糖・脂質代謝の経過をフォローしえたPTRF遺伝子変異による全身性脂肪萎縮症の一例
- 30 Sep. 2016, 日本先天代謝異常学会雑誌, 32, 191, JapaneseビタミンB12反応性を認めた軽症メチルマロニルCoAムターゼ欠損症の一例
- 2016, 小児内科 増刊号, 48, 118 - 123, Japaneseグルタル酸血症1型Introduction scientific journal
- 第27回臨床内分泌代謝Update, Nov. 2017, Japanese, 日本内分泌学会, 神戸, Domestic conferenceCGMが診断・治療に有用であったダンピング症候群の乳児例Poster presentation
- 日本小児神経学会近畿地方会, Oct. 2017, Japanese, 日本小児神経学会, 大阪, Domestic conference症候性PKDを呈した偽性副甲状腺機能低下症の8歳女児例Oral presentation
- 第59回日本先天代謝異常学会, Oct. 2017, Japanese, 日本先天代謝異常学会, 埼玉, Domestic conferenceカルニチンのみで良好な経過をたどる慢性進行型メチルマロン酸血症同胞例Poster presentation
- 第17回日本先進糖尿病治療研究会, Oct. 2017, Japanese, 日本先進糖尿病治療研究会, 新潟, Domestic conferenceFreeStyle Libreの1型糖尿病患者での測定精度に関する検討Oral presentation
- 第272回日本小児科学会兵庫県地方会, Sep. 2017, Japanese, 日本小児科学会, 姫路, Domestic conference不明熱の精査中にRadiologically Isolated Syndromeが疑われた1例Oral presentation
- 第51回日本小児内分泌学会, Sep. 2017, Japanese, 日本小児内分泌学会, 大阪, Domestic conference新生児期に高TSH血症を示した偽性副甲状腺機能低下症の乳児期BMIPoster presentation
- 第23回日本小児・思春期糖尿病研究会年次学術集会, Jul. 2017, Japanese, 日本小児・思春期糖尿病研究会, 東京, Domestic conference内科・小児科の連携強化と 主食量の自己決定による サマーキャンプ中の血糖コントロールの改善Oral presentation
- 第23回日本小児・思春期糖尿病研究会, Jul. 2017, Japanese, 日本小児・思春期糖尿病研究会, 東京, Domestic conference内科・小児科の連携強化と主食量の自己決定によるサマーキャンプ中の血糖コントロールの改善Poster presentation
- 第59回日本小児神経学会学術集会, Jun. 2017, Japanese, 日本小児神経学会, 大阪, Domestic conference乳幼児期における発達障害児の感覚特性についての検討~自閉症および知的障害特性との関連~Oral presentation
- 第60回日本糖尿病学会年次学術集会, May 2017, Japanese, 日本糖尿病学会, 名古屋, Domestic conference幼児期からの糖・脂質代謝の経過をフォローしえたPTRF遺伝子変異による全身性脂肪萎縮症の一例(ポスター発表)Poster presentation
- 第60回日本糖尿病学会年次学術集会, May 2017, Japanese, 日本糖尿病学会, 名古屋, Domestic conference幼児期からの糖・脂質代謝の経過をフォローしえたPTRF 遺伝子変異による全身性脂肪萎縮症の一例Oral presentation
- 第61回 日本小児神経学会近畿地方会, May 2017, Japanese, 日本小児神経学会, 大阪, Domestic conference不明熱を契機にRadiologically Isolated Syndromeを呈した1例Oral presentation
- 270回 日本小児科学会兵庫県地方会, May 2017, Japanese, 日本小児科学会, 尼崎, Domestic conference乳幼児感覚プロファイルを用いた発達障害児の感覚特性に関する検討Oral presentation
- 第120回 日本小児科学会学術集会, May 2017, Japanese, 日本小児科学会, 東京, Domestic conference超低出生体重児のSGA性低身長症に対する成長ホルモン治療の検討Poster presentation
- 日本小児科学会兵庫県地方会, May 2017, Japanese, 日本小児科学会, 神戸, Domestic conference先天性甲状腺機能低下症(CH)のフォロー中に偽性副甲状腺機能低下症と診断された1例Oral presentation
- 第120回 日本小児科学会学術集会, May 2017, Japanese, 日本小児科学会, 東京, Domestic conference近位筋優位の筋力低下から筋疾患が疑われたシャルコー・マリー・トゥース病2型Poster presentation
- 270回 日本小児科学会兵庫県地方会, May 2017, Japanese, 日本小児科学会, 尼崎, Domestic conferenceカーボカウントが1型糖尿病の血糖管理に有用であった7歳男児例Oral presentation
- Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, Kobe University, 01 Apr. 2019 - 31 Mar. 2022Development of novel therapy due to correcting splicing error of patients with galactosialidosisGalactosialiodosis is a rare lysosomal disease, caused by mutation in the CTSA gene. In Japanese cases, common variant, IVS7+3A>G, has been identified, which was related to the milder phenotype. However, this mechanism of genotype and phenotype was not fully declared. At first, we analyzed the splicing pattern of this variant both in vivo and vitro. In previous report, this common variant produced exon 7 skipping and normal mRNA. However, our study revealed normal mRNA was not obtained in both. Furthermore, novel alternative splicing product including gt insertion was demonstrated. Skipping of exon 7 (92 bases) was assumed to cause nonsense medicated decay, but this product could be strongly related to the milder phenotype. We planed to clarify whether the specific antisense nucleotide can modify the splicing pattern of CTSA gene or not, but we can not obtain any sufficient effect However, this new splicing variant could be the novel target of therapy with galactosialidosis.